Suppr超能文献

紧急与择期经皮二尖瓣修复术后的临床转归。

Clinical Outcomes Following Urgent vs. Elective Percutaneous Mitral Valve Repair.

机构信息

Department of Cardiology, University Hospital of León, León, Spain.

Department of Cardiology, University Hospital of León, León, Spain.

出版信息

Cardiovasc Revasc Med. 2021 May;26:6-11. doi: 10.1016/j.carrev.2020.10.025. Epub 2020 Nov 9.

Abstract

AIM

To examine procedural and clinical outcomes among patients undergoing percutaneous mitral valve repair (PMVR) within an admission for acute-decompensated heart failure (ADHF).

METHODS AND RESULTS

Prospective registry of all consecutive patients with symptomatic mitral regurgitation (MR) grade 3+ or 4+ who underwent PMVR our centre and classified in 2 groups: elective group and urgent PMVR group (within the index admission for ADHF). Echocardiographic, procedural and clinical outcomes were compared between groups. 85 patients (median age 77.0 [67.8-83.4] years, 64.7% male) were treated within the recruitment period. Among them, 17 (20%) underwent urgent MitraClip®. Urgent PMVR were at a higher risk for conventional surgery (p = 0.002) and had worse estimated prognosis according to HF risk scores (p < 0.001). Overall technical success was 100%, without differences between groups. At 30 days, no differences were found in mortality, MR reduction and in NYHA functional improvement between groups. Cumulative estimated survival free from all-cause death was 92.9% (82.4% vs. 95.6%), 89.4% (82.4% vs. 91.1%), 76.3% (82.4 vs. 74.9%) at 6 months, 1-year and 2-years, respectively, with no significant differences between urgent or elective PMVR (p = 0.769).

CONCLUSION

MitraClip® implantation can be considered as an urgent therapy during admission for ADHF.

摘要

目的

研究因急性失代偿性心力衰竭(ADHF)入院的患者行经皮二尖瓣修复术(PMVR)的程序和临床结果。

方法和结果

前瞻性登记了所有因症状性二尖瓣反流(MR)3+或4+而在我院行 PMVR 的连续患者,并分为 2 组:择期 PMVR 组和紧急 PMVR 组(因 ADHF 入院)。比较两组之间的超声心动图、程序和临床结果。在招募期间,共治疗了 85 名患者(中位年龄 77.0[67.8-83.4]岁,64.7%为男性)。其中,17 名(20%)患者接受了紧急 MitraClip®治疗。紧急 PMVR 更有可能进行传统手术(p=0.002),并且根据心力衰竭风险评分预测预后更差(p<0.001)。整体技术成功率为 100%,两组之间无差异。在 30 天时,两组之间死亡率、MR 减轻和 NYHA 功能改善无差异。无全因死亡的累积估计生存率分别为 92.9%(82.4%比 95.6%)、89.4%(82.4%比 91.1%)、76.3%(82.4%比 74.9%),在 6 个月、1 年和 2 年时,紧急或择期 PMVR 之间无显著差异(p=0.769)。

结论

MitraClip®植入术可考虑作为 ADHF 入院时的紧急治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验